2026 | International evidence base | Systematic review and meta-analysis
Wilson J et al. The Lancet Psychiatry. 2026;13:304-315.
Original publication DOI | Study record | Published correction
Methods: The review included 54 randomized trials with 2,477 participants, searching publications through May 13, 2025. Researchers assessed symptom outcomes, adverse events, risk of bias, and evidence certainty across diagnoses.
Findings: Signals of benefit appeared for some outcomes in insomnia, autism, tic disorders, and cannabis use disorder. Pooled analyses did not establish significant benefits for several other conditions, including PTSD and anxiety disorders. Overall adverse events were more frequent with cannabinoids.
Limitations: Most outcome evidence had low certainty, and 44% of trials were judged at high risk of bias. Different diagnoses and cannabinoid formulations require separate interpretation. A published correction accompanies the article; consult the corrected online paper.